Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle A Fanale

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2018
Radiation Therapy as an Effective Salvage Strategy for Secondary CNS LymphomaSarah A Milgrom, Chelsea C Pinnix, T Linda Chi, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
British Journal of Haematology|June 20, 2014
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceYasuhiro Oki, Mansoor Noorani, Pei Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution ReviewChelsea C Pinnix, Jatin J Shah, Hubert Chuang, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
Blood|May 20, 2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphomaMichelle A Fanale, Chan Yoon Cheah, Amy Rich, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2018
Radiation Therapy as an Effective Salvage Strategy for Secondary CNS LymphomaSarah A Milgrom, Chelsea C Pinnix, T Linda Chi, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
British Journal of Haematology|June 20, 2014
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceYasuhiro Oki, Mansoor Noorani, Pei Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution ReviewChelsea C Pinnix, Jatin J Shah, Hubert Chuang, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
Blood|May 20, 2017
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphomaMichelle A Fanale, Chan Yoon Cheah, Amy Rich, et al.
Pageof 9